HBP vs. FRX, PLI, ABCN, EMC, TH, BCT, IPA, SCYB, COM, and NVH
Should you be buying Helix BioPharma stock or one of its competitors? The main competitors of Helix BioPharma include Fennec Pharmaceuticals (FRX), ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Theratechnologies (TH), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Novoheart (NVH). These companies are all part of the "biotechnology" industry.
Helix BioPharma vs. Its Competitors
Fennec Pharmaceuticals (TSE:FRX) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.
Fennec Pharmaceuticals has higher revenue and earnings than Helix BioPharma. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Helix BioPharma had 4 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 4 mentions for Helix BioPharma and 0 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 0.67 beat Helix BioPharma's score of 0.19 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
Fennec Pharmaceuticals has a beta of 2.091843, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Helix BioPharma has a beta of -0.449843, suggesting that its share price is 145% less volatile than the S&P 500.
14.2% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Helix BioPharma has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Helix BioPharma's return on equity of 1,803.57% beat Fennec Pharmaceuticals' return on equity.
Summary
Fennec Pharmaceuticals beats Helix BioPharma on 10 of the 14 factors compared between the two stocks.
Get Helix BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helix BioPharma Competitors List
Related Companies and Tools
This page (TSE:HBP) was last updated on 9/13/2025 by MarketBeat.com Staff
Free HBP Stock Alerts